摘要
目的探讨靶向CD24单克隆抗体3E10对肝癌化疗效果的影响。方法以1μg/mL 3E10(3E10实验组)或1μg/mL IgG(IgG对照组)处理肝癌HuH-7细胞24~48 h。通过transwell侵袭实验检测细胞侵袭和迁移数量,通过成球实验检测细胞的克隆形成数量。背部皮下移植HuH-7细胞至CD-1?Nude无胸腺裸鼠,5 d后均分为3组(均n=5),无治疗对照组注射生理盐水,IgG对照组注射顺铂(腹腔注射1 mg/kg)联合IgG(静脉注射5 mg/kg),3E10实验组注射顺铂(腹腔注射1 mg/kg)联合3E10(静脉注射5 mg/kg),治疗周期为4周,监测肿瘤生长情况。结果处理48 h,3E10实验组HuH-7细胞的侵袭能力、迁移能力和成球能力均较IgG对照组降低,抑制率分别为(36.40±6.95)%、(41.45±2.79)%和(40.33±8.17)%(均P<0.05)。与IgG对照组比较,3E10提高顺铂对裸鼠肝癌细胞HuH-7移植瘤的抑制作用,抑制率由(37.50±6.48)%提高至(68.75±9.83)%(P<0.01)。结论靶向CD24分子3E10增强化疗药物顺铂对裸鼠肝癌移植瘤的治疗作用。
Objective To investigate the effect of monoclonal antibody 3 E10 targeting CD24 on the chemotherapy effect of hepatocellular carcinoma. Methods HuH-7 cells were treated with 1 μg/mL 3 E10 for 24 h to 48 h.The IgG-treated group(1 μg/mL) was used as control.The invasion and migration of HuH-7 cells were detected by transwell invasion assay.The number of clones of HuH-7 cells was detected by spheronization assay.HuH-7 cells were subcutaneously transplanted into the back of 15 CD-1 Nude athymic nude mice.After 5 days,the mice were divided into 3 groups,each with 5 mice.One group was injected with normal saline as the untreated control group.Another group was injected with cisplatin(1 mg/kg) combined with IgG(5 mg/kg) was used as the chemotherapy control group,and the third group was injected with cisplatin(1 mg/kg) and 3 E10(5 mg/kg) as the test group.The treatment period was 4 weeks,and the tumor growth was monitored.Results 3 E10 significantly down regulated the invasion ability,migration ability and sphere formation ability of HuH-7 cells.The inhibition rates were(36.40±6.95)%,(41.45±2.79)% and(40.33±8.17)%(all P<0.05),respectively.3 E10 significantly enhanced the inhibition effect of cisplatin on implanted hepatocellular carcinoma in nude mice,and the inhibition rate increased from(37.50±6.48)% to(68.75±9.83)%(P<0.01). Conclusion Monoclonal antibody 3 E10 targeting CD24 enhances the therapeutic effect of cisplatin on subcutaneous implanted hepatocellular carcinoma in nude mice,providing a new candidate drug for targeted therapy of liver cancer.
作者
黄泽坚
吕萍
于宝丹
方昶
程庆
Huang Zejian;Lv Ping;Yu Baodan;Fang Chang;Cheng Qing(Department of Hepatobiliary Surgery,The Sun Yat-sen Memorial Hospital of Sun Yat-sen University,Guangzhou 510210,China;Clinical and Experimental Research Center, Dermatology Hospital, SouthernMedical University, Guangzhou 510095 , China;Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120,China;Department of Cardiology,The Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510210,China)
出处
《实用肿瘤杂志》
CAS
2019年第3期215-218,共4页
Journal of Practical Oncology
基金
广东省省级科技计划项目(2014A020212235)
